pubrio
Alkem Laboratories Ltd. logo

Alkem Laboratories Ltd.

Privately Held
alkemlabs.com
製藥產業18,000+ employeesFounded 1973🇮🇳 印度

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India's largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries'.

成立年份
1973
員工
18,000+
行業
製藥產業
公司類型
Privately Held
股票
nse: ALKEM.NS
總部
🇮🇳Alkem House, Senapati Bapat Marg, Mumbai, Maharashtra, In, 400 013 (+2)
專長
研究產業製藥產業醫療保健
0 / 1
活躍市場
0
新市場
信心度
大多為早期訊號
0%
動能
對比上一週期
32 / 100
擴張評分
發展中
階段1投入中
無訊號 · 過去 90 日

全球擴張

即時
ID
階段
探索中投入中進入中營運中

市場進入時間軸

此公司進入各市場的次序 — 由最舊至最新

1
🇮🇩ID第 1st 個進入的市場 · 2025推進中
投入中
1 個訊號投入中 階段
目前階段投入中投入資源
信心度28%
開始追蹤於2025首個訊號

近期訊號

註冊以查看完整訊號動態

值得了解

關於 Alkem Laboratories Ltd. 的常見問題

關於 Alkem Laboratories Ltd. 業務、市場及增長訊號的快速解答。

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India's largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries'.

立即展開你的旅程

可以先用平台,也可以先聊聊

自行使用 Pubrio,或讓我們的團隊協助研究、挖掘潛在客戶,甚至串接資料。

Start Journey Image
pubrio

Pubrio 將 50+ 個在地來源的商業、人才與意圖數據全球化整合,讓 AI 與營收團隊掌握完整市場視野。

© 2026 Pubrio。版權所有。